Sponsor Arbaclofen/STX 209 Study for children with Autism and Fragile X.
  • Petitioned Joan Campion, Pfizer

This petition was delivered to:

Corporate / Financial Media Relations
Joan Campion, Pfizer
Corporate, Financial and Global Public Health
Mary Anne Rhyne, Glaxo Smith Kline
US Media Relations
Julie Masow, Novartis
Associate Director, Public Affairs
Chris Clark, Bristol Meyers Squibb
Head Media Relations, ROCHE
Alexander Klauser
Sanofi, US
Jack Cox, Head Media Relations
Director, Corporate Media Relations
Johnson & Johnson, Carol Goodrich
Abbott Laboratories, External Communications
Scott Davies
Corporate Media Relations (Tony Jewell):
Tony Jewell, AstraZeneca
Sr. Director Global Corporate Communications
Ed Sagebiel, Eli Lilly & Co
Corporate Communications
Jeff LeRoy, Proctor & Gamble
PR, Corporate Communications
All Pharmaceutical Companies -
MacDougall Biomedical Communications / Seaside Therapeutics PR
Kari Watson
Office of Good Clinical Practice Food and Drug Administration
FDA
LaRoche Clinical Trials
Genentech Clinical Trials
UC Davis, Sacramento
Randi Hagerman, MD
WLS Chicago
ABC News
FRAXA
Katie Clapp
National Institutes of Health
Charlotte Armstrong
National Dessemination Center for Children with Disabilities
Emory University School of Medicine, The Department of Human Genetics
Mika Nakamoto Kinoshita, M.D., Ph.D.
Rush University
Dr. Elizabeth Berry-Kravis
Illinois Governor
President of the United States
Illinois State Senate
Illinois State House
U.S. Senate
U.S. House of Representatives

Sponsor Arbaclofen/STX 209 Study for children with Autism and Fragile X.

    1. Petition by

      FX MOM Rogers

      Fort Worth, Texas

Please read Holly Roo's Story about her son (Holly and Parker pictured above) and you will see how a trial drug, Arbaclofen, has changed her life and has impacted so many others living with autism and Fragile X. Arbaclofen has had amazing results for many participants yet Seaside Therapeutics has had to immediately terminate this trial without gaining FDA approval due to lack of funding. We hope that this story, and there are thousands more, can inspire pharmaceutical companies to see that it has been a lifesaver for so many families and can definitely be profitable!!

To:
Joan Campion, Pfizer, Corporate / Financial Media Relations
Mary Anne Rhyne, Glaxo Smith Kline, Corporate, Financial and Global Public Health
Julie Masow, Novartis, US Media Relations
Chris Clark, Bristol Meyers Squibb, Associate Director, Public Affairs
Alexander Klauser, Head Media Relations, ROCHE
Jack Cox, Head Media Relations, Sanofi, US
Johnson & Johnson, Carol Goodrich, Director, Corporate Media Relations
Scott Davies, Abbott Laboratories, External Communications
Tony Jewell, AstraZeneca, Corporate Media Relations (Tony Jewell):
Ed Sagebiel, Eli Lilly & Co, Sr. Director Global Corporate Communications
Jeff LeRoy, Proctor & Gamble, Corporate Communications
All Pharmaceutical Companies -, PR, Corporate Communications
Kari Watson, MacDougall Biomedical Communications / Seaside Therapeutics PR
FDA, Office of Good Clinical Practice Food and Drug Administration
Genentech Clinical Trials, LaRoche Clinical Trials
Randi Hagerman, MD, UC Davis, Sacramento
ABC News, WLS Chicago
Katie Clapp, FRAXA
Charlotte Armstrong, National Institutes of Health
National Dessemination Center for Children with Disabilities
Mika Nakamoto Kinoshita, M.D., Ph.D., Emory University School of Medicine, The Department of Human Genetics
Dr. Elizabeth Berry-Kravis, Rush University
Illinois Governor
President of the United States
Illinois State Senate
Illinois State House
U.S. Senate
U.S. House of Representatives
Sponsor Arbaclofen, STX 209 Clinical Trials and Studies for Chidren with Autism and Fragile X.

Sincerely,
[Your name]

Recent signatures

    News

    1. Reached 4,000 signatures
    2. Decision-maker Angel Investors of Chicago responds:

      Angel Investors of Chicago

      Angel Investors of Chicago

      businessplan@angelinvestorsofchicago.com

      STOP SENDING THIS TO ABOVE

      WE ARE NOT and don't want to be involved


    3. Decision-maker Angel Investors of Chicago responds:

      Angel Investors of Chicago

      Angel Investors of Chicago

      businessplan@angelinvestorsofchicago.com

      STOP SENDING THIS TO ABOVE

      WE ARE NOT and don't want to be involved


    4. Decision-maker Angel Investors of Chicago responds:

      Angel Investors of Chicago

      STOP SENDING THIS TO THE ABOVE


    5. Decision-maker Angel Investors of Chicago responds:

      Angel Investors of Chicago

      STOP SENDING THIS TO THE ABOVE


    6. Decision-maker Angel Investors of Chicago responds:

      Angel Investors of Chicago

      STOP SENDING THIS TO THE ABOVE


    7. Decision-maker Angel Investors of Chicago responds:

      Angel Investors of Chicago

      STOP SENDING THIS TO THE ABOVE


    8. Decision-maker Angel Investors of Chicago responds:

      Angel Investors of Chicago

      STOP SENDING THIS TO THE ABOVE


    9. Decision-maker Angel Investors of Chicago responds:

      Angel Investors of Chicago

      stop sending me this stuff


    10. Reached 2,000 signatures

    Supporters

    Reasons for signing

    • rosa guajardo HERMOSILLO, MEXICO
      • 5 months ago

      mi hijo de 14 años sufre de sindrome de asperger y tiene episodios de agresividad contra él y otros ,le he dado Risperidona ,pero por los efectos secundarios deje de darle, me receto el psiquiatra Ritalin pero no quisimos darle porque tambien tiene efectos secundarios y leimos que en

      E.E.U.U ya no la dan, ahora le doy solo tes de hierbas para el estres y flores de bach pero los episodios de ira y agresividad no cesan aunque despues cuando se calma reconoce que estuvo mal ,pero no sabemos si lo siente realmente o lo dice para que le levantemos el castigo ( sin computadora por unos días).les agradeceria muchisimo que siguieran con las investigaciones y pusieran a la venta lo antes posible este medicamento

      REPORT THIS COMMENT:
    • Connie Kranz GOODWIN, SD
      • 6 months ago

      I have 4 grandchildren with Fragile X. This MATTERS to me

      REPORT THIS COMMENT:
    • Jaime Brewer LINCOLN, NE
      • 6 months ago

      I have 1 daughter (age 6) and 3 nephews (ages 17-22) living with Fragile X Syndrome. Our family like many others, are looking and praying for a medication that will help with their debilitating symptoms...please give us a chance.

      REPORT THIS COMMENT:
      • 6 months ago

      My daughter has Fragile X syndrome, I really wish someone will continue studying this drug.

      REPORT THIS COMMENT:
      • 6 months ago

      This drug can be an answer to my daughter who has FXS!

      REPORT THIS COMMENT:

    Develop your own tools to win.

    Use the Change.org API to develop your own organizing tools. Find out how to get started.